Development of a Novel Nonradioisotopic Assay and Cdc25B Overexpression Cell Lines for Use in Screening for Cdc25B Inhibitors.

CONCLUSION: The nonradioisotopic Cdk1 kinase assay and Cdc25B overexpression cell lines developed in this study can be conveniently used as tools for screening inhibitors of Cdc25B phosphatase as anticancer drugs. PMID: 30187708 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30187708?dopt=Abstract

Source: Yonsei Medical Journal - September 8, 2018 Category: Universities & Medical Training Authors: Ha GS, Lee CM, Kim CW Tags: Yonsei Med J Source Type: research

More News: Environmental Health | Eye Cancers | Retinoblastoma | Study | Tetracycline